30 June 2025
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Director/PDMR Shareholding
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immunology and oncology markets, advises that Dr Simon Sinclair, Non-Executive Director has purchased ordinary shares of £0.01 each in the Company ("Ordinary Shares"), as detailed below:
| Number of Ordinary Shares Acquired | Average Price Paid per Share | Total Consideration Paid | Number of Ordinary Shares Now Held | % of Company's Issued Capital |
| 72,507 | 1.37 pence | £995.01 | 108,428 | 0.07% |
-ENDS-
Enquiries:
| Roquefort Therapeutics plc | +44 (0)20 3918 8633 |
| Stephen West (Chairman) / Dr Darrin Disley (Interim MD) | |
| SP Angel Corporate Finance LLP (Broker) David Hignell / Vadim Alexandre / Devik Mehta | +44 (0) 20 3470 0470
|
| Burson Buchanan (Public Relations) Ben Romney / Jamie Hooper | +44 (0)20 7466 5000
|
| Peak IR (Investor Relations) Seb Wykeham | +33 (0)7 44 44 15 42 |
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the immunology and oncology markets prior to securing a value accretive exit.
Roquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer and immunology assets.
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com
This announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("UK MAR").
The notification below, made in accordance with the requirements of the UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Simon Sinclair | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Director | |
| b) | Initial notification /Amendment | Initial | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Roquefort Therapeutics plc | |
| b) | LEI | 254900P4SISIWOR9RH34 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.01 par value
ISIN: GB00BMDQ2T15 | |
| b) | Nature of the transaction | Purchase of 72,507 ordinary shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | 1.37 pence per share | 72,507 | |
| d | Aggregated information - Aggregated volume - Price |
- 72,507 - 1.37p | |
| e) | Date of the transactions | 27 June 2025 | |
| f) | Place of the transactions | London Stock Exchange (XLON); Main Market | |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.